Medicines

Fulltext search

For help on how to get the results you want, see our search tips.

Search results

129 results

Medicine European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter Orphan designations Remove Orphan designations filter Direct healthcare professional communication Remove Direct healthcare professional communication filter

Categories Human Remove Human filter

Medicine type Exceptional circumstances Remove Exceptional circumstances filter Accelerated assessment Remove Accelerated assessment filter

Sort by

List item

Human medicine European public assessment report (EPAR): Empliciti

Elotuzumab, Multiple Myeloma
Date of authorisation: 11/05/2016, , Revision: 11, Authorised, Last updated: 06/03/2023
List item

Human medicine European public assessment report (EPAR): Maviret

glecaprevir, pibrentasvir, Hepatitis C, Chronic
Date of authorisation: 26/07/2017, , Revision: 21, Authorised, Last updated: 02/03/2023
List item

Human medicine European public assessment report (EPAR): Vyndaqel

tafamidis, Amyloidosis
Date of authorisation: 16/11/2011, , , , Revision: 25, Authorised, Last updated: 02/03/2023
List item

Human medicine European public assessment report (EPAR): Onpattro

patisiran sodium, Amyloidosis, Familial
Date of authorisation: 27/08/2018, , , , Revision: 10, Authorised, Last updated: 28/02/2023
List item

Human medicine European public assessment report (EPAR): Lamzede

velmanase alfa, alpha-Mannosidosis
Date of authorisation: 23/03/2018, , , , Revision: 6, Authorised, Last updated: 22/02/2023
List item

Human medicine European public assessment report (EPAR): Strensiq

asfotase alfa, Hypophosphatasia
Date of authorisation: 28/08/2015, , , , Revision: 16, Authorised, Last updated: 15/02/2023
List item

Human medicine European public assessment report (EPAR): Sylvant

siltuximab, Giant Lymph Node Hyperplasia
Date of authorisation: 22/05/2014, , , Revision: 12, Authorised, Last updated: 09/02/2023
List item

Human medicine European public assessment report (EPAR): Harvoni

ledipasvir, Sofosbuvir, Hepatitis C, Chronic
Date of authorisation: 17/11/2014, , Revision: 27, Authorised, Last updated: 09/02/2023
List item

Human medicine European public assessment report (EPAR): Sovaldi

Sofosbuvir, Hepatitis C, Chronic
Date of authorisation: 16/01/2014, , Revision: 27, Authorised, Last updated: 09/02/2023
List item

Human medicine European public assessment report (EPAR): Defitelio

defibrotide, Hepatic Veno-Occlusive Disease
Date of authorisation: 18/10/2013, , , , Revision: 14, Authorised, Last updated: 09/02/2023
List item

Human medicine European public assessment report (EPAR): Evrysdi

Risdiplam, Muscular Atrophy, Spinal
Date of authorisation: 26/03/2021, , , Revision: 3, Authorised, Last updated: 06/02/2023
List item

Human medicine European public assessment report (EPAR): Pandemic Influenza Vaccine H5N1 Baxter AG

influenza vaccine (whole virion, inactivated) containing antigen of: A/Vietnam/1203/2004 (H5N1), Influenza, Human; Immunization; Disease Outbreaks
Date of authorisation: 16/10/2009, , Revision: 8, Authorised, Last updated: 06/02/2023
List item

Human medicine European public assessment report (EPAR): Coagadex

Human coagulation factor X, Factor X Deficiency
Date of authorisation: 16/03/2016, , , Revision: 9, Authorised, Last updated: 25/01/2023
List item

Human medicine European public assessment report (EPAR): Praxbind

idarucizumab, Hemorrhage
Date of authorisation: 20/11/2015, , Revision: 11, Authorised, Last updated: 18/01/2023
List item

Human medicine European public assessment report (EPAR): Atriance

nelarabine, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Date of authorisation: 22/08/2007, , , Revision: 26, Authorised, Last updated: 16/01/2023
List item

Human medicine European public assessment report (EPAR): Elaprase

idursulfase, Mucopolysaccharidosis II
Date of authorisation: 08/01/2007, , , Revision: 25, Authorised, Last updated: 15/12/2022
List item

Human medicine European public assessment report (EPAR): Nyxthracis (previously Obiltoxaximab SFL)

nyxthracis, Anthrax
Date of authorisation: 18/11/2020, , , , Revision: 3, Authorised, Last updated: 15/12/2022
List item

Human medicine European public assessment report (EPAR): Takhzyro

lanadelumab, Angioedemas, Hereditary
Date of authorisation: 22/11/2018, , , , Revision: 10, Authorised, Last updated: 13/12/2022
List item

Human medicine European public assessment report (EPAR): Jorveza

Budesonide, Esophageal Diseases
Date of authorisation: 08/01/2018, , , Revision: 6, Authorised, Last updated: 06/12/2022
List item

Human medicine European public assessment report (EPAR): Zytiga

abiraterone acetate, Prostatic Neoplasms
Date of authorisation: 05/09/2011, , Revision: 26, Authorised, Last updated: 06/12/2022
List item

Human medicine European public assessment report (EPAR): Zynteglo

Autologous CD34+ cell enriched population that contains haematopoietic stem cells transduced with lentiviral vector encoding the βA-T87Q-globin gene, beta-Thalassemia
Date of authorisation: 29/05/2019, , , , , Revision: 5, Withdrawn, Last updated: 30/11/2022
List item

Human medicine European public assessment report (EPAR): Tagrisso

osimertinib mesilate, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 01/02/2016, , Revision: 17, Authorised, Last updated: 29/11/2022
List item

Human medicine European public assessment report (EPAR): Scenesse

afamelanotide, Protoporphyria, Erythropoietic
Date of authorisation: 22/12/2014, , , , Revision: 9, Authorised, Last updated: 04/11/2022
List item

Human medicine European public assessment report (EPAR): Raxone

idebenone, Optic Atrophy, Hereditary, Leber
Date of authorisation: 08/09/2015, , , , Revision: 8, Authorised, Last updated: 27/10/2022
List item

Human medicine European public assessment report (EPAR): Myalepta

Metreleptin, Lipodystrophy, Familial Partial
Date of authorisation: 29/07/2018, , , , Revision: 7, Authorised, Last updated: 27/10/2022